XYTOS announces its shares will resume Trade in Germany!

October 30, 2011
XYTOS INC (PINK:XYTS) traded as high as $.35 during Friday’s trading session and managed to close with a 7.14% gain as the company announced shares will resume trading in the German market. The stock has traded as high as $1.23 over the past 52 weeks and is now more than 75% off that high – keep an eye on more volume to pour in as more investors find out about the news!
After months of Due Diligence on the company by the German Regulators, XYTOS was cleared to start trading in Germany on September 12, 2011. Unfortunately there were additional unexpected delays while the company worked to get the German Shares available for electronic settlement through the Clearstream Clearing System. XYTOS is now pleased to announce that as of earlier this week all necessary steps have been completed and the company can now move forward with plans to establish an Actively Trading Market for our Euro Shares in Germany. Get my next ALERT 100% FREE
Additionally, in line with company planning, the completion of this process in Germany immediately opened the door for the company’s European Investors to join our U.S. Shareholders in support of the company in the U.S. Market.
XYTOS appreciates the support of our loyal shareholders and for this reason every calculated step by the company is done with the shareholders in mind. With this said, XYTOS is focused on creating a strong stock price and shareholder base, and as the company’s Bio-Medical future unfolds through upcoming news announcements, shareholders will clearly see the focused directions that management has put in place to make XYTOS a Global Leader in the Introduction of Advance Medical Procedures.
Further, as XYTOS continues to grow in the Capital Markets on two continents; and as the company continues to implement simple supply side economics by limiting the number of shares in the market, management feels that we will bring the stock price in line with other companies in our sector that has far less technology to offer. Additionally, with XYTOS working in new areas of Advanced Medical Procedures, it must be understood that the company may occasionally encounter unexpected delays as it takes Regulators (both Medical and Financial) time to understand certain aspects of the company’s Advanced Bio-Medical Technologies. Any such delay on a specific Bio-Medical Technology should appear seamless to shareholders since the company has multiple technologies to introduce.
Finally, upcoming announcements will further detail the progress the company has made in setting a solid financial foundation for the company’s future. This solid foundation will allow the company to then start announcing details of Advance Medical Procedures that the company will be introducing to the Global Medical Community.
As the company brings in new shareholders, as always, we would like those shareholders that are looking for periodic updates, via email, to opt in at shareholders@xytos.com.
XYTOS, working at the forefront of the “Science of Medicine,” is a Bio-Medical Technologies Company concentrating on the Research, Development, and Introduction of Next Generation Medicine and Medical Procedures in the areas of Stem Cell Therapies, Tissue Engineering, Cellular Medicine, and Cancer. (Read more)


About StockPreacher.com
StockPreacher.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
StockPreacher Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. StockPreacher.com is a wholly owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.